Boris Quednow
Professor of Psychiatry and Psychopharmacology
Data updated
Research Footprint
Boris Quednow appears in 10 tracked papers (2007–2026), most studied alongside MDMA, Ayahuasca and Placebo, across Healthy Volunteers, Interpersonal Functioning & Social Connectedness and Medicinal Chemistry & Drug Development.
Most-cited paper: MDMA enhances emotional empathy and prosocial behavior (355 citations).
Frequent co-authors: Milan Scheidegger, Andrea Steuer and Erich Seifritz.
Background & Research
Boris B. Quednow is a clinician‑scientist whose work sits at the intersection of psychopharmacology, neuropsychiatry and experimental medicine. He has led and contributed to controlled human studies examining the behavioural and neurochemical effects of recreational and therapeutic psychoactive compounds, including comparative investigations of MDMA and methamphetamine, magnetic resonance spectroscopy studies of glutamate and GABA in relation to chronic MDMA use, neurophysiological assessments of conflict monitoring and emotional processing, and factorial dose‑escalation work probing the pharmacokinetic and pharmacodynamic interaction between N,N‑dimethyltryptamine (DMT) and the monoamine oxidase inhibitor harmine in healthy volunteers.
Key Impact
A leading translational researcher known for experimental studies on MDMA, methamphetamine and serotonergic compounds that link neurochemical and neurophysiological measures to social‑cognitive and behavioural outcomes.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Boris Quednow is associated with.
Psychiatric University Hospital, Zurich
The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →